Frederick Wolfe is a scholar working on Rheumatology, Psychiatry and Mental health and Pharmacology.
According to data from OpenAlex, Frederick Wolfe has authored 205 papers receiving a total of 24.4k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Rheumatology, 71 papers in Psychiatry and Mental health and 58 papers in Pharmacology. Recurrent topics in Frederick Wolfe's work include Rheumatoid Arthritis Research and Therapies (102 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (71 papers) and Musculoskeletal pain and rehabilitation (46 papers). Frederick Wolfe is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (102 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (71 papers) and Musculoskeletal pain and rehabilitation (46 papers). Frederick Wolfe collaborates with scholars based in United States, Germany and Canada. Frederick Wolfe's co-authors include Kaleb Michaud, Robert S. Katz, Winfried Häuser, I. Jon Russell, Donna Hawley, Mary‐Ann Fitzcharles, Don L. Goldenberg, M A Cathey, Anthony S. Russell and Philip J. Mease and has published in prestigious journals such as The Lancet, PLoS ONE and Pain.
In The Last Decade
Frederick Wolfe
204 papers
receiving
23.4k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
20102.9k citationsFrederick Wolfe, Mary‐Ann Fitzcharles et al.Arthritis Care & Researchprofile →
The prevalence and characteristics of fibromyalgia in the general population
19951.9k citationsFrederick Wolfe et al.Arthritis & Rheumatismprofile →
Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia
20111.1k citationsFrederick Wolfe, Mary‐Ann Fitzcharles et al.The Journal of Rheumatologyprofile →
The mortality of rheumatoid arthritis
19941.1k citationsFrederick Wolfe, M A Cathey et al.Arthritis & Rheumatismprofile →
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
2014839 citationsFrederick Wolfe et al.Annals of the Rheumatic Diseasesprofile →
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Countries citing papers authored by Frederick Wolfe
Since
Specialization
Citations
This map shows the geographic impact of Frederick Wolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick Wolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick Wolfe more than expected).
This network shows the impact of papers produced by Frederick Wolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick Wolfe. The network helps show where Frederick Wolfe may publish in the future.
Co-authorship network of co-authors of Frederick Wolfe
This figure shows the co-authorship network connecting the top 25 collaborators of Frederick Wolfe.
A scholar is included among the top collaborators of Frederick Wolfe based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Frederick Wolfe. Frederick Wolfe is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Yocum, David E., Frederick Wolfe, Jimin Han, et al.. (2007). The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice.. Document Server@UHasselt (UHasselt).1 indexed citations
10.
Chakravarty, Eliza F., Kaleb Michaud, & Frederick Wolfe. (2005). Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.. PubMed. 32(11). 2130–5.157 indexed citations
11.
Ethgen, Olivier, Kristijan H. Kahler, Sheldon X. Kong, Jean‐Yves Reginster, & Frederick Wolfe. (2002). The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis.. PubMed. 29(6). 1147–55.69 indexed citations
12.
Wolfe, Frederick. (2000). The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis.. PubMed. 27(3). 630–7.158 indexed citations
13.
Wolfe, Frederick. (1999). "Silicone related symptoms" are common in patients with fibromyalgia: no evidence for a new disease.. PubMed. 26(5). 1172–5.31 indexed citations
14.
Ehrich, Elliot, Thomas J. Schnitzer, Harris McIlwain, et al.. (1999). Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.. PubMed. 26(11). 2438–47.132 indexed citations
Wolfe, Frederick & J. Potter. (1996). FIBROMYALGIA AND WORK DISABILITY. Rheumatic Disease Clinics of North America. 22(2). 369–391.32 indexed citations
Wolfe, Frederick, et al.. (1993). Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy.. PubMed. 20(5). 797–802.22 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.